Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

6.1%

3 terminated/withdrawn out of 49 trials

Success Rate

93.6%

+7.1% vs industry average

Late-Stage Pipeline

88%

43 trials in Phase 3/4

Results Transparency

50%

22 of 44 completed trials have results

Key Signals

22 with results

Enrollment Performance

Analytics

Phase 3
43(87.8%)
Phase 2
5(10.2%)
N/A
1(2.0%)
49Total
Phase 3(43)
Phase 2(5)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (49)

Showing 20 of 49 trials
NCT00310180Phase 3Active Not Recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Role: collaborator

NCT00003140Phase 3Completed

Letrozole After Tamoxifen in Treating Women With Breast Cancer

Role: collaborator

NCT00433511Phase 3Active Not Recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Role: collaborator

NCT00066690Phase 3Completed

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Role: collaborator

NCT00490139Phase 3Completed

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Role: collaborator

NCT00324805Phase 3Completed

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Role: collaborator

NCT00003375Phase 2Completed

Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Role: collaborator

NCT00754845Phase 3Completed

Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

Role: collaborator

NCT00066573Phase 3Completed

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Role: collaborator

NCT00005957Not ApplicableCompleted

Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

Role: collaborator

NCT00008385Phase 3Completed

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

Role: collaborator

NCT00101283Phase 2Completed

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Role: collaborator

NCT00002872Phase 3Completed

Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions

Role: collaborator

NCT00003808Phase 2Completed

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

Role: collaborator

NCT00028990Phase 3Completed

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Role: collaborator

NCT00003519Phase 3Completed

Combination Chemotherapy in Treating Women With Breast Cancer

Role: collaborator

NCT00003010Phase 3Completed

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

Role: collaborator

NCT00004125Phase 3Completed

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Role: collaborator

NCT00533949Phase 3Completed

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Role: collaborator

NCT00127205Phase 3Completed

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

Role: collaborator